The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 18, 2022

Filed:

Oct. 16, 2020
Applicant:

Molecular Templates, Inc., Austin, TX (US);

Inventors:

Eric Poma, New York, NY (US);

Erin Willert, Round Rock, TX (US);

Jack Higgins, Georgetown, TX (US);

Assignee:

Molecular Templates, Inc., Austin, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/38 (2006.01); C07K 14/25 (2006.01); A61P 35/00 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); C07K 16/32 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 14/25 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); A61P 35/00 (2018.01); C07K 16/32 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01);
Abstract

Provided herein are HER2-targeting molecules comprising Shiga toxin A Subunit derived polypeptides having 1) de-immunization and 2) reduced, protease-cleavage sensitivity while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity via ribosome inhibition. Certain HER2-targeting molecules of the present invention exhibit reduced immunogenic potential in mammals and are well-tolerated by mammals while retaining aforementioned features. The HER2-targeting molecules of the present invention have uses for selectively killing specific cells (e.g., HER positive tumor cells); for selectively delivering cargos to specific cells (e.g., HER positive tumor cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving the expression or over-expression of cell-surface HER2.


Find Patent Forward Citations

Loading…